Journal of Neurology and Neuroscience

  • ISSN: 2171-6625
  • Journal h-index: 18
  • Journal CiteScore: 4.35
  • Journal Impact Factor: 3.75
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • The Global Impact Factor (GIF)
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Scientific Journal Impact Factor (SJIF)
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
Share This Page

Short Communication - (2023) Volume 14, Issue 4

Exploring the molecular basis of Alzheimer's disease: Novel pathways and targets

Sara Coetzer*
Department of Neurorehabilitation, University Hospital of Toulouse, Hôpital de Rangueil, 31400 Toulouse, France
*Correspondence: Sara Coetzer, Department of Neurorehabilitation, University Hospital of Toulouse, Hôpital de Rangueil, 31400 Toulouse, France, Email:

Received: 01-Aug-2023, Manuscript No. ipjnn-23-14065; Editor assigned: 03-Aug-2023, Pre QC No. P-14065; Reviewed: 17-Aug-2023, QC No. Q-14065; Revised: 23-Aug-2023, Manuscript No. R-14065; Published: 31-Aug-2023


Alzheimer's disease (AD) poses a formidable challenge to global healthcare, with its prevalence on the rise as the population ages. Understanding the intricate molecular underpinnings of AD is imperative to develop effective therapeutic strategies. This paper embarks on a journey into the molecular landscape of Alzheimer's disease, aiming to unearth novel pathways and targets. By exploring the latest research findings, this study seeks to shed light on promising avenues for intervention and treatment. The quest for novel insights into the molecular basis of AD promises to deepen our understanding of this devastating condition and offers hope for innovative approaches to combat its progression [1,2].


The description section provides a comprehensive overview of the paper's content. It delves into the intricacies of Alzheimer's disease, highlighting its growing impact on global health. Furthermore, it explores the multifaceted molecular aspects of AD, encompassing amyloid-beta and tau pathology, neuroinflammation, oxidative stress, and synaptic dysfunction. The paper reviews recent research findings and breakthroughs in the field, focusing on emerging pathways and targets that show promise for therapeutic development. Moreover, it discusses the role of genetics and epigenetics in AD susceptibility, emphasizing the importance of personalized medicine approaches. The description underscores the significance of elucidating novel pathways, such as the gut-brain axis, neurovascular dysfunction, and the role of glial cells, in AD pathogenesis [3].

In addition, the paper addresses the potential of cuttingedge technologies, including advanced imaging techniques and omics approaches, in unraveling the molecular complexities of AD. It also explores ongoing clinical trials and experimental treatments targeting these novel pathways and targets, highlighting the transformative potential of precision medicine in AD management. In addition to reviewing the molecular mechanisms driving AD, this paper explores the innovative tools and technologies that have revolutionized our ability to study these processes. It discusses the use of advanced imaging techniques, such as Positron Emission Tomography (PET) and functional Magnetic Resonance Imaging (fMRI), to visualize diseaserelated changes in the brain [4].

Moreover, it addresses the potential of emerging therapies, including monoclonal antibodies, small molecules, and gene-based approaches, that target novel pathways and represent the next frontier in Alzheimer's disease treatment. In summary, this comprehensive exploration of the molecular basis of Alzheimer's disease not only sheds light on the intricacies of the disease but also offers a roadmap for future research and therapeutic development. By uncovering novel pathways and targets, we move closer to the ultimate goal of developing effective treatments and interventions that can alleviate the burden of AD on individuals and society as a whole [5].


In conclusion, delving into the molecular basis of Alzheimer's disease reveals a complex and evolving landscape. While much progress has been made in understanding traditional pathways like amyloidbeta and tau, the exploration of novel pathways and targets presents exciting opportunities for therapeutic intervention. By embracing a multidisciplinary approach that combines genetics, epigenetics, neuroscience, and advanced technologies, we can unlock new insights into AD pathogenesis.

The quest for novel insights offers hope to millions of individuals affected by AD and their families. It is a testament to the relentless pursuit of knowledge and innovation in the face of one of the most pressing health challenges of our time. As we continue to explore the molecular basis of Alzheimer's disease, we draw closer to the prospect of effective treatments and, ultimately, a world where the devastating impact of AD is mitigated and, one day, eradicated.



Conflict of Interest



  1. Khan F, Joshi A, Devkota HP, et al. Dietary glucosinolates derived isothiocyanates: Chemical properties, metabolism and their potential in prevention of Alzheimer’s disease. Front Pharmacol. 2023;14.
  2. Google Scholar, Crossref, Indexed at

  3. Vicentini FA, Keenan CM, Wallace LE, et al. Intestinal microbiota shapes gut physiology and regulates enteric neurons and glia. Microbiome. 2021;1-24.
  4. Google Scholar, Crossref, Indexed at

  5. Kim MS, Kim Y, Choi H, et al. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer’s disease animal model. Gut. 2020;69(2):283-94.
  6. Google Scholar, Crossref, Indexed at

  7. Hoffman JD, Parikh I, Green SJ, et al. Age drives distortion of brain metabolic, vascular and cognitive functions, and the gut microbiome. Front Aging Neurosci. 2017;9:298.
  8. Google Scholar, Crossref, Indexed at

  9. Chen Y, Fang L, Chen S, et al. Gut microbiome alterations precede cerebral amyloidosis and microglial pathology in a mouse model of Alzheimer’s disease. Biomed Res Int 2020;2020.
  10. Google Scholar, Crossref, Indexed at